Science menu


Our mission is to revolutionise ADC development

Antibody Drug Conjugates (ADCs) represent a powerful addition to cancer treatment, with a mechanism that permits the delivery of potent cytotoxic agents directly to cancer cells using monoclonal antibodies that target tumour-specific antigens.

This selective approach to delivery of tumour killing payloads results in superior efficacy and fewer side effects for patients.

Stability – solving the problem in the clinic

Currently, there are over 80 ADCs in the clinic, comprised of a selection of toxin classes, numerous linkers and a wide range of antibodies, directed towards many distinct antigens.

Iksuda’s approach is straightforward – we are focused on the targeted delivery of potent, next generation DNA damaging payloads to solid cancers to treat the broadest patient population possible.

Improving therapeutic index